The macro factors Stoke Therapeutics STOK discussed in earnings Q4 2025 Profit Disappoints Is COMPASS CMPS stock a good opportunity for entry Q4 2025 EPS Misses Views How Matson MATX responds to market challenges Investor Concern 20260508 How Pyrophyte PAII performance compares to expectations 010 20260506